BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 04, 2013
 |  BioCentury  |  Emerging Company Profile

Kite: Immune system rewrite

Kite reprogramming T cells with technology from NCI for cancer immunotherapy

Kite Pharma Inc. thinks its autologous T cell technology can address multiple malignancies regardless of the underlying mechanism or biology. It says the platform has shown durable efficacy following a single dose in trials at the National Cancer Institute.

Kite was founded in 2009 to develop cancer immunotherapies and in 2011 licensed DC-AdGM-CAIX from the University of California, Los Angeles. The therapy comprises dendritic cells engineered to express a fusion protein of carbonic anhydrase IX (CAIX) and granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2).

The product is in a Phase I trial in patients with clear cell renal cell carcinoma (RCC).

Last October, Kite signed a Cooperative Research and Development Agreement (CRADA) with NCI in which the biotech received access to an autologous T cell technology to treat hematological and solid cancers.

According to Kite President and CEO Aya Jakobovits, the CRADA covers the development of current...

Read the full 741 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >